''Çok düşük riskli mesane kanseri'' Kas-invaziv olmayan mesane kanserlerinde gerçekten yeni bir alt grup mu?
Abstract
Giriş: Düşük
riskli mesane kanserinin klinik sonuçlarını analiz ederek “çok düşük riskli”
mesane kanserinin öngörücü rollerini değerlendirmeyi amaçladık
Gereç
ve yöntem: 2013 ve Aralık 2019 tarihleri arasında düşük riskli NMIBC
tanısı ile tedavi ve takip edilen 32 hasta retrospektif olarak incelendi.
Hastalar tümör büyüklüğüne göre iki prognostik gruba ayrıldı (≤1,0 cm ve
>1,0 cm). İki grup klinik, patolojik bulgular ve nüks, takipte ilerleme
açısından karşılaştırıldı.
Bulgular:
Toplam 32 hasta rekürrens görülme süresine kadar takip edildi. Toplam 14
hastada, tümör boyutu 1 cm altında idi. Tek değişkenli Cox modellemesinde,
sigara içme durumu ve intravezikal mitomisin C (MMC), rekürrens için daha kısa
süre ile anlamlı derecede ilişkiliydi (sırasıyla,
HR 0,103, %95 CI 0,020-0,520, p=0,006; HR 4,264, %95 CI 1,026-17,727, p=0,046).
Tümör boyutunun bağımsız öngörü faktörü olarak rekürrens zamanını etkilemediği
görüldü (p=0,838).
Sonuç:
Düşük
riskli KİOMK tanısı alan hastalarda önerilen çok düşük riskli grup
modellemesinde, 1 cm altı olarak belirlenen grup ile 1 cm üstü tümörlerde
rekürrens açısından anlamlı farklılık izlenmedi.
Keywords
Mesane kanseri düşük riskli mesane kanseri kas invaziv olmayan mesane kanseri rekürrens prognoz
References
- Referans1 Stewart BW, Wild CP, eds. World Cancer Report 2014. International Agency for Research on Cancer, Lyon, France, 2014. Referans2 Kirkali Z, Chan T, Manoharan M et al. Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology 2005;66:4–34. DOI:10.1016/j.urology.2005.07.062 Referans3 Babjuk M, Bohle A, Burger M et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016. Eur Urol 2017;71:447–461. DOI: 10.1016/j.eururo.2016.05.041 Referans4 Burger M, Catto JW, Dalbagni G et al. Epidemiology and risk factors of urothelial bladder cancer. Eur Urol 2013;63:234–241 DOI: 10.1016/j.juro.2016.06.049 Referans5 Babjuk M, Burger M, Compérat EM et al. European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ) - 2019 Update. Eur Urol 2019;76:639-657. DOI: 10.1016/j.eururo.2019.08.016 Referans6 Gofrit ON, Pode D, Pizov G et al. ‘Very-low-risk’ bladder tumours – a new entity? BJU Int 2018;121:627–631. DOI: 10.1111/bju.14108 Referans7 Sylvester RJ, van der Meijden AP, Oosterlinck W et al. Predicting recurrence and progression in individual patients with stage TaT1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006;49:466–477.
Is ''Very-low-risk'' really a new subgroup of bladder cancers that are non-muscle-invasive bladder cancer?
Abstract
Introductıon: We
aimed to evaluate the predictive roles of “very-low-risk” bladder cancer by
analyzing the clinical outcomes of low-risk bladder cancer
Materıal and Methods: 32
patients who were treated and followed up between 2013 and December 2019 with
the diagnosis of low-risk NMIBC were retrospectively analyzed. Patients were
divided into two prognostic groups based on tumor size (≤1.0 cm vs >1.0 cm).
Two groups were compared in terms of clinical, pathological findings and
recurrence, progression in follow-up.
Results: A
total of 32 patients were followed up to recurrence time. A total of 14 patients
had tumors that were ≤1,0 cm. Using univariate Cox modeling, smoking status
and Intravesical Mitomycin C (MMC) were significantly associated with shorter
time to recurrence (HR 0.103 95% CI 0.020-0,520, P = 0.006; HR 4.264 95% CI
1.026-17.727, P = 0.046; respectively ) . Tumor size was not significantly
associated with any differences in time to recurrence (P = 0,838).
Conclusion: Lower tumors (≤1.0 cm) are not significantly
associated with shorter time to recurrence compared with larger tumors (>1.0
cm).
Keywords
Bladder cancer Kaplan–Meier low-risk bladder cancer non-muscle-invasive bladder cancer prognosis
References
- Referans1 Stewart BW, Wild CP, eds. World Cancer Report 2014. International Agency for Research on Cancer, Lyon, France, 2014. Referans2 Kirkali Z, Chan T, Manoharan M et al. Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology 2005;66:4–34. DOI:10.1016/j.urology.2005.07.062 Referans3 Babjuk M, Bohle A, Burger M et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016. Eur Urol 2017;71:447–461. DOI: 10.1016/j.eururo.2016.05.041 Referans4 Burger M, Catto JW, Dalbagni G et al. Epidemiology and risk factors of urothelial bladder cancer. Eur Urol 2013;63:234–241 DOI: 10.1016/j.juro.2016.06.049 Referans5 Babjuk M, Burger M, Compérat EM et al. European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ) - 2019 Update. Eur Urol 2019;76:639-657. DOI: 10.1016/j.eururo.2019.08.016 Referans6 Gofrit ON, Pode D, Pizov G et al. ‘Very-low-risk’ bladder tumours – a new entity? BJU Int 2018;121:627–631. DOI: 10.1111/bju.14108 Referans7 Sylvester RJ, van der Meijden AP, Oosterlinck W et al. Predicting recurrence and progression in individual patients with stage TaT1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006;49:466–477.
Details
| Primary Language | Turkish |
|---|---|
| Subjects | Urology |
| Journal Section | Research Article |
| Authors | |
| Publication Date | September 18, 2020 |
| Submission Date | May 8, 2020 |
| Acceptance Date | June 29, 2020 |
| Published in Issue | Year 2020 Volume: 13 Issue: 3 |
